Compare Amphastar Pharmaceuticals Inc (AMPH) vs Axon Enterprise Inc (AXON) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

Axon trades at $565.80, down 2.78% today, with a bullish technical signal from moving averages and strong analyst support. Recent earnings show mixed quarterly beats, with Q2 2026 results pending. The company maintains solid revenue growth, reaching $2.78 billion in 2025, though valuation ratios like P/E of 228.15 appear elevated. Positive news includes a Zacks Strong Buy upgrade and federal rulings favoring nonlethal enforcement technology.

Outlook remains positive with an 80.95% analyst buy rating and $640.33 consensus price target, suggesting 13% upside. Key risks include high valuation sensitivity and execution challenges in scaling software services. Investor sentiment is buoyed by institutional interest and strategic expansions in counter-drone capabilities.